Pfizer Inc. (NYSE:PFE) Shares Acquired by Lynch & Associates IN

Lynch & Associates IN increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,433 shares of the biopharmaceutical company’s stock after purchasing an additional 1,929 shares during the period. Pfizer makes up about 2.8% of Lynch & Associates IN’s portfolio, making the stock its 8th biggest holding. Lynch & Associates IN’s holdings in Pfizer were worth $8,769,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PFE. Evolution Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter valued at $34,000. Winch Advisory Services LLC raised its holdings in Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 336 shares in the last quarter. Ruggie Capital Group acquired a new position in Pfizer in the 4th quarter valued at $44,000. Karp Capital Management Corp acquired a new position in Pfizer in the 4th quarter valued at $53,000. Finally, HMS Capital Management LLC acquired a new position in Pfizer in the 2nd quarter valued at $71,000. 71.82% of the stock is owned by institutional investors and hedge funds.

In related news, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction on Monday, May 13th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $850,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Several brokerages have weighed in on PFE. Zacks Investment Research raised Green Brick Partners from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Bank of America boosted their price target on Tc Pipelines from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley reissued an “overweight” rating and set a $25.00 price target (up previously from $22.00) on shares of Mylan in a report on Tuesday. Goldman Sachs Group raised Solaredge Technologies from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $35.00 to $52.00 in a report on Monday, June 17th. Finally, Barclays reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 9th. Sixteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $46.00.

PFE stock traded down $2.34 during midday trading on Tuesday, reaching $39.11. 47,242,276 shares of the stock were exchanged, compared to its average volume of 17,756,490. The company has a market cap of $239.58 billion, a PE ratio of 13.04, a PEG ratio of 2.50 and a beta of 0.64. Pfizer Inc. has a 52 week low of $38.14 and a 52 week high of $46.47. The company has a quick ratio of 1.27, a current ratio of 1.54 and a debt-to-equity ratio of 0.60. The firm has a fifty day moving average of $43.19.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. Pfizer’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.88 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 3.68%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Cost of equity and a company’s balance sheet

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.